Karen E. Duff

Karen E. Duff

Auto-generated profile, based on publicly available information

Karen E. Duff

UK Dementia Research Institute, University College London, London, UK

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JLJada Lewis
Jada Lewis
EMEileen McGowan
Eileen McGowan
JRJulia Rockwood
Julia Rockwood
HMHeather Melrose
Heather Melrose
PNParimala Nacharaju
Parimala Nacharaju
MHMike Hutton
Mike Hutton

1 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLi Liu
Li Liu
VDValerie Drouet
Valerie Drouet
JWJessica W. Wu
Jessica W. Wu
MWMenno P. Witter
Menno P. Witter
SSScott A. Small
Scott A. Small
KDKaren Duff
Karen Duff
Tauopathy in the brain of patients with Alzheimer's disease starts in the entorhinal cortex (EC) and spreads anatomically in a defined pattern. To test whether pathology initiating in the EC spreads through the brain along synaptically connected circuits, we have generated a transgenic mouse model that differentially expresses pathological human tau in the EC and we have examined the distribution of tau pathology at different timepoints. In relatively young mice (10–11 months old), human tau was present in some cell bodies, but it was mostly observed in axons within the superficial layers of the medial and lateral EC, and at the terminal zones of the perforant pathway. In old mice (>22 months old), intense human tau immunoreactivity was readily detected not only in neurons in the superficial layers of the EC, but also in the subiculum, a substantial number of hippocampal pyramidal neurons especially in CA1, and in dentate gyrus granule cells. Scattered immunoreactive neurons were also seen in the deeper layers of the EC and in perirhinal and secondary somatosensory cortex. Immunoreactivity with the conformation-specific tau antibody MC1 correlated with the accumulation of argyrophilic material seen in old, but not young mice. In old mice, axonal human tau immunoreactivity, especially at the endzones of the perforant pathway, was greatly reduced. Relocalization of tau from axons to somatodendritic compartments and propagation of tauopathy to regions outside of the EC correlated with mature tangle formation in neurons in the EC as revealed by thioflavin-S staining. Our data demonstrate propagation of pathology from the EC and support a trans-synaptic mechanism of spread along anatomically connected networks, between connected and vulnerable neurons. In general, the mouse recapitulates the tauopathy that defines the early stages of AD and provides a model for testing mechanisms and functional outcomes associated with disease progression.

1 August 2016 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JWJessica W Wu
Jessica W Wu
SHS Abid Hussaini
S Abid Hussaini
IBIsle M Bastille
Isle M Bastille
GRGustavo A Rodriguez
Gustavo A Rodriguez
AMAna Mrejeru
Ana Mrejeru
KDKaren E Duff
Karen E Duff
The authors show that tau can be released by neurons and transferred to other neurons via the extracellular space. Moreover, they show that enhancing neuronal activity accelerates transneuronal tau propagation and exacerbates tau pathology. Tau protein can transfer between neurons transneuronally and trans-synaptically, which is thought to explain the progressive spread of tauopathy observed in the brain of patients with Alzheimer's disease. Here we show that physiological tau released from donor cells can transfer to recipient cells via the medium, suggesting that at least one mechanism by which tau can transfer is via the extracellular space. Neuronal activity has been shown to regulate tau secretion, but its effect on tau pathology is unknown. Using optogenetic and chemogenetic approaches, we found that increased neuronal activity stimulates the release of tau in vitro and enhances tau pathology in vivo. These data have implications for disease pathogenesis and therapeutic strategies for Alzheimer's disease and other tauopathies.

2 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WNWendy Noble
Wendy Noble
EPEmmanuel Planel
Emmanuel Planel
CZCindy Zehr
Cindy Zehr
VOVicki Olm
Vicki Olm
JMJordana Meyerson
Jordana Meyerson
KDKaren Duff
Karen Duff
Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with itin vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be hyperphosphorylated in Alzheimer's disease and significantly reduced levels of aggregated, insoluble tau. Administration of a second GSK-3 inhibitor also correlated with reduced insoluble tau levels, supporting the idea that lithium exerts its effect through GSK-3 inhibition. Levels of aggregated tau correlated strongly with degree of axonal degeneration, and lithium-chloride-treated mice showed less degeneration if administration was started during early stages of tangle development. These results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically.

24 September 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
HFHONGJUN (Harry) FU
HONGJUN (Harry) FU
JHJohn Hardy
John Hardy
KDKaren E. Duff
Karen E. Duff

22 December 2013 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
UKUsman A Khan
Usman A Khan
LLLi Liu
Li Liu
FPFrank A Provenzano
Frank A Provenzano
DBDiego E Berman
Diego E Berman
CPCaterina P Profaci
Caterina P Profaci
SSScott A Small
Scott A Small